CRO KCR expands further into Western Europe

By Zahcary Brennan

- Last updated on GMT

KCR, CRO, Europe, Germany, UK, clinical development
KCR, CRO, Europe, Germany, UK, clinical development
European CRO KCR has registered two new entities in the UK and Germany, which adds to its presence in 18 countries in Europe as well as the US. 

The registration of new entities in the UK and Germany is part of the company’s strategy to bring the business closer to Western European customers and further deepen client relationships.

KCR has a history of supporting projects in these countries​,” KCR CEO Mike Jagielski told Outsourcing-Pharma.com. “From that point of view, the decision to expand in these regions has been a logical step.

In addition, we also have long standing agreements with a network of medical and operations experts in these countries. UK, Germany and France remain key research markets and it is important for our European Strategy to directly provide the support​.”

Eyes East

KCR offers three types of professional contract research services: clinical development services, functional service provision and post-marketing clinical services for a spectrum of therapeutic areas.

We are able to directly cover large part of Europe without the consideration of subcontracting​,” Jagielski told us. “In addition, we see the boundaries between CEE [Central and Eastern Europe] and Western Europe are being more and more reduced​.

Companies will decide to go to Europe and less and less it will be a decision about CEE or Western Europe. KCR has to be prepared for that​.”

He added that the company already has partnerships with locally based or represented companies in the UK and Germany. “It will also equip KCR with local law benefits and make our business cooperation easier. The next country we aim for is France​,” Jagielski added.

Since its early days of forging a path in CEE, KCR continues to develop and expand east and across Western Europe. Having a local team in each of the offices gives the company a unique insight into local regulations, the company said, noting extensive relationships with key opinion leaders and principal investigators.

KCR will support Phase II through Phase IV studies in the UK and Germany, Jagielski said.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars